Nitroxinil Market

The Nitroxinil market is projected to grow at a CAGR of 4.7% from 2025 to 2035, driven by increasing prevalence of parasitic infections in livestock, rising demand for effective flukicides, and growing emphasis on improving animal health and productivity. Nitroxinil is a halogenated phenol derivative used as an anthelmintic agent, primarily effective against blood-feeding parasites such as Fasciola hepatica (liver flukes) and certain gastrointestinal nematodes. It acts by uncoupling oxidative phosphorylation in parasite mitochondria, leading to energy depletion and parasite death.

Primarily used in veterinary medicine, Nitroxinil is administered via subcutaneous injection for the treatment and control of fascioliasis in cattle and sheep. It is often integrated into livestock parasite management programs, particularly in regions with a high prevalence of liver fluke infections. Nitroxinil’s ability to target mature and immature flukes makes it a valuable tool in reducing parasite burden, preventing economic losses due to decreased productivity, and improving herd health.

Europe and Latin America dominate the Nitroxinil market, owing to high livestock density, routine fluke control programs, and veterinary regulations that support effective deworming. The Asia-Pacific region is expected to register the fastest growth due to expanding livestock populations, increased awareness of fluke-borne diseases, and improving access to veterinary care. North America maintains a steady market share, while parts of Africa show growth potential supported by government-led animal health initiatives and efforts to boost livestock productivity in rural economies.